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weet syndrome (SS) is classified as a neutro-
philic dermatosis based on its chief clinico-
pathologic findings: sudden onset of painful,
tender erythematous skin lesions (papules, plaques,
and nodules) and a diffuse infiltrate of mature
neutrophils in the dermis.1,2 The skin eruptions,
which most frequently present on the face, neck,
trunk, and upper extremities, are generally accom-
panied by signs of systemic inflammation including
pyrexia, malaise, and arthralgia.3
First-line therapy for SS is systemic corticosteroids,
which typically yield immediate relief from pyrexia
and rapid resolution of skin lesions.3 Alternatives
include saturated solution of potassium iodide
(SSKI), colchicine, dapsone, indomethacin, sulfapyr-
idine, and tumor necrosis factor antagonists.1,3,4
This report discusses 2 women who had SS for a
period longer than expected. There were no factors
such as malignancy or SS-inducing medication discov-
ered to be the cause of SS in these patients. Both
women responded well to treatment with prednisone;
however, skin lesions returned immediately upon
attempts to taper themedication.We believe that these
cases represent a chronic variant of classical SS, which
may be considered in patients who have persistent
SS-characteristic skin lesions for over 4 months.CASE REPORTS
Case 1
A 50-year-old woman presented with a 4-month
history of annular and arcuate red papules on her
back, neck, chest, arms, and thighs. The patient was
afebrile and reported mild pruritus and facial edema.
Initially, 2 skin biopsies found neutrophil-rich dermal
inflammation consistent with SS. Vasculitis was not
seen. Skin lesions regressed with prednisone, but thethe University of Toledo College of Medicinea and the
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hs.upenn.edu.patient experienced severe flares when tapering the
medication to less than 40 mg/d (Fig 1). Routine
examinations for malignancy, including complete
blood counts and serum protein electrophoresis, and
autoimmune disease were negative. Outbreaks of SS
consisted of fever, annular erythematous patches, or
blood-filled bullae. Periodically, she complained of
facial edema, hand swelling, and arthralgia. She
stopped treatment with prednisone for about
8 months, during which time the patient continued
to experience low-grade activity of SS. A biopsy
performed during a flare confirmed active SS.
Laboratory tests found elevated white blood cells
and neutrophils. Such flares were treated with pred-
nisone (40 mg/d). Medical history was notable for
pulmonary hyalinizing granuloma, with biapical
pleural masses and mediastinal adenopathy. The
biopsy specimen showed classic features of this rare
disease,with no evidence ofmalignancy, granulomas,
amyloid, or IgG4 staining. This condition has been
stable for more than 10 years and has no association
with SS. She stopped Dapsone, SSKI, colchicine, and
topical steroids because they were ineffective or not
tolerated. Currently she is treated with sulfapyridine.
After 5 years of follow-up, there is no evidence of
malignancy despite a thorough workup.
Case 2
A 73-year-old woman presented for evaluation of
a 9-month history of skin eruptions involving herJAAD Case Reports 2016;2:227-9.
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Fig 1. Well-demarcated edematous pink papules on the
face and neck. Rare ecchymotic patches at sites of prior
lesions are also shown.
Fig 2. Papillary dermal edema with underlying neutro-
philic infiltrate.
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found numerous red macules and plaques, some
with a bullous appearance, and scattered hyperpig-
mented macules. She reported no associated fever.
Skin biopsy found neutrophil-rich dermal infiltrate
with papillary dermal edema (Fig 2), and SS was
diagnosed. Laboratory values for white blood cells
and neutrophils were elevated. Persistence of the
eruption despite termination of all medications
eliminated the possibility of drug-induced Sweet
syndrome. The patient had lung cancer diagnosed
5 months after her initial visit and malignant mela-
noma 19 months later. These diseases could have
supported a diagnosis of malignancy-associated
Sweet syndrome; however, active SS skin lesions
confirmed through skin biopsy persisted even after
tumor excision and cancer remission. Intermittent
evaluations for malignancy over the ensuing
22 months (lung cancer) and 8 months (melanoma)
were negative, as were autoantibody screenings.
Serum protein electrophoresis found no evidence
of an M-spike. Skin lesions resolved promptly with
prednisone. When prednisone was tapered to less
than 40 mg/d, the patient flared and had burning
skin eruptions with swelling, painful serous-filled
bullae, edematous patches and plaques, and vesicu-
lopustules on edematous and erythematous skin.
Doxycycline, SSKI, dapsone, colchicine, anakinra,
indomethacin, and topical corticosteroids were inef-
fective or not tolerated. Sulfapyridine was instituted
as a steroid-sparing drug, which allowed for tapering
of prednisone to 10 mg/d. This combined treatment
allowed for low-grade activity of SS with asymptom-
atic skin lesions. To date, she has been followed up
and treated for SS for more than 4 years.
DISCUSSION
Aside from the unusual duration of symptoms, the
2 patients in this report had typical clinical, labora-
tory, and histopathologic features of SS; respondedrapidly to systemic corticosteroids; and flared off
treatment. Generally, SS patients are expected to
remit within several weeks of treatment unless there
is evidence of an underlying illness or use of disease-
associated medication.3 The cases in this report
represent chronic SS with no identifiable triggers
including connective tissue disease or autoimmune
syndromes.
Typically, SS can be explained by cytokine stim-
ulation, either via medications (granulocyte colony-
stimulating factor), malignancy (myelodysplastic
syndrome [MDS]/leukemia), or postinfection (viral
upper respiratory infections or viral gastroenteritis),
with resultant immune stimulation.3,5,6 Patients with
chronic SS may have underlying higher levels of
proneutrophil cytokines or chemotaxins that drive
neutrophil migration to the skin or may have an
aberrant, hyperactive cytokine response to minor
skin trauma (ie, pathergy caused by innocuous skin
pressure or trauma). However, the mechanism of
chronic inflammation remains unclear.
In recent years, there has been mention of
patients with chronic SS in whom MDS developed
years later.7-9 Initial skin biopsies of those patients
were often histologically atypical and found lym-
phocytic or histiocytoid infiltrates, as opposed to
SS-characterizing neutrophilic dermal infiltration.
Despite the visualization of myeloperoxidase-
positive lymphocytic or histiocytic infiltrates, chronic
SS was diagnosed without an underlying cause. It is
important to note that these studies explored the
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whichwasdiagnosedup to13years after thediagnosis
of SS.We have not considered downstreamMDS as an
explanation for chronic SS in our patients because
there was no evidence of histologically atypical skin
lesions, and complete blood counts and peripheral
smears were normal. Both patients were referred to
hematologists for further evaluation, and a bone
marrow biopsy was deemed unnecessary.
Chronic SS may present as a lone entity. The
womenpresented in this report continue to be treated
for SS more than 4 years after diagnosis. Despite the
rapid and complete resolution of skin lesions with
prednisone, the medication could not be tapered
without the recurrence of severe skin eruptions.REFERENCES
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